Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cancer cells, including those in chronic myelogenous leukemia (CML), can exhibit chromosomal translocations leading to oncogenic fusion proteins like BCR-ABL.
• Tyrosine kinase inhibitors (imatinib, dasatinib) are effective against CML but long-term treatment can lead to drug resistance.
• Downregulating BCR-ABL protein expression presents an alternative therapeutic strategy for CML.

Purpose of the Study:

• To introduce the development and potential of Specific and Nongenetic inhibitor of apoptosis protein [IAP]-dependent Protein Erasers (SNIPER) as a novel therapeutic strategy for CML.
• To explore the mechanism of SNIPER in inducing targeted protein degradation.
• To discuss the prospects of SNIPER for overcoming BCR-ABL-mediated drug resistance in CML.

Main Methods:

• Development of hybrid molecules (SNIPER) designed to target specific proteins.
• Utilizing the inhibitor of apoptosis protein (IAP)-dependent pathway for protein knockdown.
• Investigating the induction of ubiquitylation and proteasomal degradation of target proteins.

Main Results:

• SNIPER technology enables targeted degradation of specific proteins.
• The system leverages IAP-mediated ubiquitylation and proteasomal pathways.
• SNIPER demonstrates potential for downregulating oncogenic fusion proteins like BCR-ABL.

Conclusions:

• SNIPER represents a promising new approach for targeting BCR-ABL in CML.
• This protein knockdown system offers a potential strategy to overcome drug resistance in CML therapy.
• Further development of SNIPER holds significant therapeutic promise for CML patients.